We studied the effect of troglitazone, a new oral antidiabetic agent t
hat potentiates insulin action and reduces insulin resistance, on albu
minuria in streptozotocin (STZ)-treated diabetic rats. Without affecti
ng blood glucose level, blood pressure, and creatinine clearance, trog
litazone treatment of diabetic rats significantly decreased the diabet
es-associated albuminuria at all time points studied (4 to 12 weeks of
treatment: diabetic 510 +/- 161 mu g/24 h v diabetic treated 112 +/-
34 mu g/24 h at 12 weeks, P<.05), These data suggest that troglitazone
has potential in the treatment of diabetic nephropathy. Copyright (C)
1997 by W.B. Saunders Company.